Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fludarabine + cytarabine + busulfan + antithymocyte globulin + melphalan + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- Fujian Medical University Union Hospital
- Modality
- Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination is a complex myeloablative conditioning (MAC) regimen utilized in the context of haploidentical-cord blood hematopoietic stem cell transplantation (haplo-cord HSCT). It consists of the purine analog fludarabine, the antimetabolite cytarabine, the alkylating agents busulfan, melphalan, and cyclophosphamide, and the immunosuppressive antithymocyte globulin (ATG). Developed by Fujian Medical University Union Hospital, the regimen is specifically designed for patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). The protocol employs a sequential infusion strategy where cyclophosphamide is administered within a critical window to balance myeloablative intensity and immunomodulation, facilitating the engraftment of both haploidentical stem cells and umbilical cord blood.
- Other names
- FA5Cy2Bu3 conditioning regimenFA-5Cy2Bu3 conditioning regimenFA 5Cy2Bu3 conditioning regimen
02
Targets
POLA1 (DNA polymerase alpha)RNR (Ribonucleotide reductase)DNA-directed primase/polymerase protein (PrimPol)POLD1 (DNA polymerase delta)DNA
Beyond the preview
Go deeper on fludarabine + cytarabine + busulfan + antithymocyte globulin + melphalan + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fludarabine + cytarabine + busulfan + antithymocyte globulin + melphalan + cyclophosphamide.